Are National Cardiac Guidelines being Applied by Vascular Surgeons?  by Cassar, K et al.
Are National Cardiac Guidelines being Applied
by Vascular Surgeons?
K. Cassar,1 J. J. F. Belch2 and J. Brittenden1*
1Vascular Surgical Unit, University of Aberdeen, Aberdeen; and 2Peripheral Vascular Disease Research Unit,
University of Dundee, Dundee, Scotland, UK
Introduction. National cardiac guidelines recommend that patients with intermittent claudication should be managed in
the same way as those with established coronary heart disease. This survey aimed to determine the attitudes of vascular
consultants to risk factor management in new patients attending their out-patient clinic.
Methods. An anonymous postal questionnaire was sent to all 394 members of the Vascular Surgical Society in June 2002.
Questions were asked about the following measures: serum cholesterol levels, the presence of diabetes, antiplatelet therapy,
exercise regimens, blood pressure, thrombophilia, smoking and the availability of local guidelines and expertise.
Results. A response rate of 65% was obtained. Most (85%) consultants would measure a random cholesterol, but 34%
would only treat claudicants if the cholesterol was greater than 5.5 mmol/l. Furthermore, 23% would inappropriately use
diet alone as initial cholesterol lowering therapy. Over a quarter of consultants would not screen for diabetes or measure
blood pressure. Nearly all (99%) would recommend aspirin and 66% would recommend nicotine replacement therapy. Only
55% had access to a smoking cessation clinic, and 34% to a formal exercise program. The majority (56%) did not have local
risk factor management guidelines, only 16% had access to a vascular physician, and 65% would prefer to have this expertise
available for difficult cases.
Discussion. Management of major risk factors was found to be sub-optimal. Thus guidelines for the prevention of coronary
disease in clinical practice are not being applied to claudicants.
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Introduction
Intermittent claudication affects between 1.7%1 and
7.1%2 of the population over 55 years of age. Housley,
in a 1988 leading article summarized the treatment of
claudication as merely ‘Stop smoking and keep
walking’.3 Since then the major risk factors for both
cardiac and peripheral arterial disease (PAD) have
become well established, and treatment strategies
devised. The Joint British recommendations on pre-
vention of coronary heart disease in clinical practice
published in 1998 stated that patients with PAD
should be managed in the same way as those with
established coronary heart disease (CHD).4 These
guidelines state that patients with CHD or other
major atherosclerotic disease such as claudication
should: receive lifestyle intervention in order to
discontinue smoking and increase aerobic exercise,
be prescribed aspirin and screened for the presence of
diabetes by performing a fasting blood glucose.
Rigorous control of blood pressure (BP) and lipids is
also recommended with the following targets: BP less
than 140 mmHg systolic and less than 85 mmHg
diastolic and total cholesterol less than 5.0 mmol/l.
Apart from this consensus document, there are no
national guidelines in the UK, which deal specifically
with risk factor modification in these patients. In 1998,
the Scottish Intercollegiate Guidelines Network also
published a document on ‘Drug Therapy for Periph-
eral Vascular Disease’, which recommend that all
patients should be prescribed aspirin.5
Unfortunately, despite these recommendations,
current evidence suggests that risk factor management
in claudicants in patients with claudication in the
primary care setting is sub-optimal.6,7 It is apparent
that the national guidelines for the prevention of
coronary disease in clinical practice are not being
applied to claudicants in this setting. Furthermore a
recent survey of 337 general practitioners found that
18% considered risk factor modification to be primary
and not secondary.6 Thus, currently the main oppor-
tunity for these patients to be appropriately managed
is at their hospital visit. What is unclear is how well
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vascular surgeons manage these risk factors or,
whether, they assume that they are being investigated
and treated in primary care. The aim of this study was
to determine, by means of a postal questionnaire, the
attitudes and practice of vascular consultants to risk
factor management in new patients with intermittent
claudication attending the out-patient clinic.
Materials and Methods
A postal survey questionnaire was sent to all 394
members of the Vascular Surgical Society of Great
Britain and Ireland in June 2002. Simple tick box style
questions were asked about the following major risk
factors: dyslipidaemia serum cholesterol, presence of
diabetes, prescribing of antiplatelet therapy, exercise
regimens, elevated BP, and smoking (see Appendix A).
The measurement of the other less well recognized risk
factors thrombophilia and hyperhomocysteine were
also assessed. Consultants were also asked their own
age range, type of hospital in which they practised
(District General or Teaching), the availability of local
guidelines and expertise when required. The ques-
tionnaire was anonymous and thus no reminders
could be sent.
Replies were received from 256 consultants, result-
ing in a response rate of 65%. The figures given below
are valid percentages, which take into account missing
responses to individual questions in the completed
questionnaires. Unless otherwise stated, this
accounted for less than 10% of the responders.
Comparison between types of hospital and consultant
age were performed using chi-squared test with Yates
correction.
Results
Major risk factors: lack of prescribing of antiplatelet therapy,
diabetes, dyslipidaemia, smoking, lack of exercise and
elevated BP
A response rate of 65% was obtained. The number
of consultants that would screen and treat these risk
factors is shown in Table 1. If we first consider
antiplatelet therapy, in this survey 98% of consultant
vascular surgeons would routinely recommend
aspirin therapy for patients with intermittent clau-
dication. The majority, 82% would prescribe 75 mg,
12% would recommend 150 mg, 5% 300 mg and 1%
would use a range of doses. If aspirin were
contraindicated, 94% would recommend clopidogrel,
another platelet agent. The remaining 6% (14)
consultants would recommend dipyridamole ðn ¼
12Þ; aspirin and lanzoprazole ðn ¼ 1Þ and nothing
ðn ¼ 2Þ:
Over a quarter of consultants would not routinely
screen for diabetes or measure BP (Table 1). The
cholesterol levels at which treatment would be
recommended is shown in Table 2. The initial
cholesterol lowering treatment would be diet alone
in 23%, diet and lipid-lowering drugs in 56% and
lipid lowering drugs alone in 17%. A further 4%
used a combination of these treatment options.
Fourteen percent (33) of consultants exercised an
age limit for prescribing statins. Thirty-one of these
consultants stated their age limit for statin therapy
to be: over 60, n ¼ 1; over 70, n ¼ 3; 75 and over
n ¼ 10; 80 and over, n ¼ 16; and 90 and over n ¼ 1:
There was also considerable variation in the levels
of triglycerides that consultants would treat ranging
from 1.5 to 6 mmol/l. In addition, 23% of consult-
ants said that they were unsure what level to treat
or would refer for specialist advice.
Twenty-seven percent of consultant vascular sur-
geons would not routinely measure a systolic and
diastolic BP in patients with claudication attending
their clinic. This measurement was more likely to be
performed by the older consultants. Nineteen percent
of responders did not complete the section regarding
the level of BP at which they would recommend the
GP to recheck it. For those that did complete this
question, there were considerable variations in
response (Fig. 1).
Fig. 1. Blood pressure at which consultant would rec-
ommend GP to monitor.
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Homocysteine and thrombophilia
Many consultants stated that these investigations were
not locally available. Homocysteine levels would be
checked by 28 and 14% would screen for thrombophi-
lia in younger patients. For those surgeons who would
perform a thrombophilia screen, only 16% would do
so in patients older than 55 years.
Local guidelines and access to a vascular physician
In response to the question ‘In cases where risk factor
management is not straight forward would you wish
the involvement of a vascular physician’, 65% of
consultant surgeons answered yes. Only 16% of
consultants had access to a ‘vascular physician’
which in some cases was considered to be the local
cardiologist. Local guidelines on the management of
risk factors in patients with intermittent claudication
were available to 44% of consultant vascular surgeons.
Consultants’ age and hospital type
Sixty percent of consultants (135) worked in district
general and 40% (91) in teaching hospitals, 12% (30)
did not fill in this question. Responses to the
questionnaire were analysed with respect to place of
work and age, less than or older than 50 (Tables 3 and
4). There were no statistical differences in age range in
those who responded and worked in a District General
or Teaching Hospital.
Discussion
Patients with intermittent claudication have as high a
risk of developing or dying from CHD as many
patients surviving their first myocardial infarction.4
Yet, this survey has revealed deficiencies in the
management of many of the risk factors in patients
with intermittent claudication undertaken by consult-
ant vascular surgeons. This includes many of the
better known and understood risk factors—dyslipi-
daemia, diabetes, smoking, lack of exercise and
hypertension. Although we are unable to comment
on the 35% of consultants who did not reply a response
rate of 65% is acceptable and we believe does allow us
to draw conclusions with regards to practice within
the UK.
The importance of risk factor management in
patients with claudication has become increasingly
recognized and has been the subject of a number of
recent reviews.8,9 One reason why risk factor manage-
ment is suboptimal may due to the lack of mortality
studies in this area, although this is now being
addressed. It may also be due to a mistaken assump-
tion by vascular surgeons that risk factor management
is being performed by primary care.6 A number of
studies have shown that risk factor management in
new patients attending the clinic is sub-optimal.6,10
Alternatively, there may be a conceptual problem with
applying national cardiac guidelines to what are
perceived to be non-cardiac patients. This may also
apply to other high-risk groups such as patients with
cerebrovascular disease. In a recent survey, we have
shown that 18% of general practitioners consider risk
factor management to constitute primary and not
secondary prevention in claudicants.6
Table 1. Screening and management of secondary risk factors.
Risk factor Screening/management Absolute/total responders for each question (percentage of
responders*)
Antiplatet therapy Routinely prescribe aspirin 246/251 (98)
Diabetes Routinely measure random glucose 165/250 (66)
Ask GPs to measure fasting glucose 74/225 (33)
Perform none of the above 65/250 (26)
Dyslipidaemia Measure fasting triglyceride 147/191 (77)#
Measure serum cholesterol 240/284 (85)
Blood pressure Routinely measure 182/249 (73)
Exercise Access to formal exercise program 86/253 (34)
Smoking Recommend patient to stop 242/244 (99)
Access to a non-smoking clinic 137/249 (55)
Recommend nicotine replacement therapy 155/235 (66)
*Values in parenthesis are valid percentages, which take into account missing responses to individual questions in the completed
questionnaires (this was less than 10% apart from #).
Table 2. Level of cholesterol at which vascular consultants initiate
treatment.
What level of cholesterol would you treat? Number n ¼ 233 (%)
,5 mmol/l 20 (9)
.5 mmol/l 104 (46)
.5.5 mmol/l 65 (28)
.6 mmol/l 16 (6)
All levels 28 (12)
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The Joint British Recommendations on prevention
of CHD4 has stated that what evidence there is
available supports the treatment of patients with
intermittent claudication with statins with the aim of
reducing the serum cholesterol to less than 5 mmol/
l.11 – 13 It is thus disappointing that 34% of consultant
vascular surgeons would only treat claudicants if the
cholesterol was greater than 5.5 mmol/l. The use of
diet alone as initial cholesterol lowering therapy by
23% of surgeons is inappropriate as many papers have
shown that it is only possible to lower cholesterol on
average by about 10%, unless the patient is very obese
and loses a significant amount of weight.14 Further-
more, with levels at or above 6 mmol/l no diet will
achieve acceptable cholesterol levels. The effect of
statin therapy in patients with isolated PAD has only
recently been addressed in the MRC Heart Protection
study.15 Published 1 month following the initiation of
this questionnaire, this study has demonstrated that
treatment with simvastatin 40 mg daily resulted in a
25% reduction in the rates of myocardial infarction,
stroke and of revascularisation in patients with PAD
irrespective of the initial cholesterol level. These data
have been widely available over the past 6 months and
account for the fact that 11% of vascular surgeons in
this survey would treat all patients irrespective of their
cholesterol level.
In the Framingham Trial, the age-adjusted risk ratio
for intermittent claudication in diabetic patients
compared to controls was five times greater for men
and four times greater for women.16 Furthermore
although diabetic patients make up about 20% of the
PAD population, 80% of amputations are in this
group.17 The Joint British Recommendations on pre-
vention of CHD4 recommends that all patients with
PAD should be screened for the presence of diabetes.
Undiagnosed diabetes is common and occurs in up to
12% of new claudicants attending the surgical out-
patient clinic.6 It is thus disappointing that 26% of
consultant vascular surgeons did not screen for
diabetes. This compares to 23% of GPs who in a recent
survey would also not screen for diabetes in patients
with claudication.6
The Joint British Recommendations on prevention
of CHD4 recommends that all patients with PAD
receive lifestyle intervention in order to discontinue
smoking and increase aerobic exercise. Cigarette
smoking is acknowledged to be ‘the single most
powerful risk factor associated with the aetiology
and clinical progression of peripheral arterial dis-
ease’.8 The excess risk of CV disease diminishes within
4–6 years after smoking cessation unlike the increased
cancer risk on.18 A Cochrane review of 108 random-
ised controlled trials has found that nicotine replace-
ment therapy is effective as part of a strategy to
promote smoking cessation and increase quit rates
approximately 1.5–2-fold.19 The effect of nicotine
replacement therapy is largely independent of any
additional support. It is perhaps surprising that only
64% of consultants would recommend nicotine repla-
cement therapy to claudicants. This figure was lower
for the older consultants and those working in district
Table 3. Screening for diabetes, hyperlipidaemia, hypertension and nicotine replacement therapy in claudicants: impact of consultant
age.
Yes ,50 years ðn ¼ 143Þ Yes, .50 years ðn ¼ 86Þ P value chi-squared
Routinely measure random glucose 100 (70%) 52 (61%) 0.087
Ask general practitioners to measure fasting glucose 42 (29%) 25 (29%) 0.38
Routinely measure lipid values 123 (86%) 68 (79%) 0.067
Routinely measure blood pressure 100 (70%) 68 (79%) 0.047*
Recommend nicotine replacement therapy 99 (69%) 44 (51%) 0.004**
*p , 0:05; **p , 0:01; chi-squared with Yates correction. Values in parenthesis represent percentage of consultants who would perform
relevant investigation.
Table 4. Screening for risk factors and treatment: impact of type of hospital.
Yes, District N ¼ 134 Yes, Teaching N ¼ 90 P value chi-squared
Routinely measure random glucose 96 (72%) 54 (60%) 0.052
Ask general practitioners to measure fasting glucose 38 (28%) 28 (31%) 0.348
Routinely measure lipid values 118 (88%) 69 (77%) 0.012*
Routinely measure blood pressure 100 (75%) 67 (74%) 0.36
Recommend nicotine replacement therapy 79 (59%) 62 (68%) 0.023*
Access to anti-smoking clinic 68 (51%) 58 (64%) 0.011*
Access to a vascular physician 15 (11%) 22 (25%) 0.007*
Local guidelines available 50 (37%) 51 (58%) 0.003*
Access to an exercise program 45 (34%) 33 (37%) 0.29
*p , 0:05; **p , 0:01; chi-squared with Yates correction.
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general hospitals. Supervised exercise has been clearly
shown to be of benefit, not only in terms of secondary
prevention but also in its ability to increase patients’
walking distance in structured programs.20 It is thus
unfortunate that 67% of vascular surgeons did not
have access to a formal exercise program.
Screening for hyperhomocysteine and thrombo-
philia are clearly not routine investigation for most
vascular surgeons and are only performed by 28 and
11%, respectively. Hyperhomocysteinaemia is an
independent risk factor for atherosclerosis and may
be present in 50–60% of patients with PAD.21,22
Thrombophilia abnormalities may occur in 30–60%
of patients with peripheral vascular disease, and are
increasingly recognized in patients who have failed
arterial intervention due to thrombosis.23,24 How-
ever, there is currently no convincing evidence that
treatment in patients who are not undergoing
interventions will alter the natural history of the
disease.25
This survey has revealed a lack of local guidelines
and implies that there may be a lack of resources
available for antismoking clinics and exercise pro-
grams. It has also shown that the majority of vascular
surgeons would welcome additional expertise input
from vascular physicians for difficult cases. Currently,
this help is only available to 16% of consultant
vascular surgeons.
Guidelines will soon be produced which specifi-
cally address risk factor management of patients with
intermittent claudication. However, strategies to
ensure their implementation are urgently required
both in primary and secondary care.
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Appendix A: Questionnaire.
Where do you work? District general, teaching hospital
What age are you? ,40 40–49 50–59 60þ
The following questions concern the management of new patients presenting at your clinic with intermittent claudication
LIPIDS
If the patient’s lipid values are not known, would you routinely measure them? YES NO
At what level of cholesterol would you recommend treatment? ,5 mmol/L, .5 mmol/L
.5.5 mmol/L, .6 mmol/L,
other please give details
For triglyceride measurement would you ask that your patient be fasted? YES NO
What level of triglyceride would you treat?
What would be your initial cholesterol lowering treatment? Diet alone
Diet and lipid-lowering drugs
Lipid-lowering drugs alone
Do you have an age limit for recommending that a statin is prescribed? YES NO (if yes, what age?)
DIABETES MELLITUS
If the patient is not known to be diabetic, do you routinely measure a random blood glucose? YES NO
Would you ask the general practitioner to measure a fasting blood glucose? YES NO
Do you check HbA1c levels? YES NO
EXERCISE
Do you have access to a formal exercise programme? YES NO
ANTIPLATELET TREATMENT
Would you routinely recommend that that aspirin should be prescribed? YES NO
If you routinely prescribe aspirin, what dose do you select? 75 mg, 150 mg or 300 mg
If aspirin was contradicted/not tolerated, would you recommend clopidogrel? YES NO
If not, what would you recommend?
CIGARETTE SMOKING
Do you advise these patients to stop smoking? YES NO
Do you recommend nicotine replacement therapy? YES NO
Do you have access/or run a smoking cessation clinic? YES NO
HYPERTENSION
Do you routinely measure patients’ arm systolic and diastolic pressure? YES NO
At what level would you recommend the general practitioner to recheck? .120/80 .130/85 .140/90
.160/100
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THROMBOPHILIA
Do you routinely check for thrombophilia? YES NO
Do you have an age limit for checking for thrombophilia? Age of onset of vascular disease ,45 ,55 ,65 .75
If you do test for thrombophilia what tests do you carry out?
In young people with vascular disease do you routinely check for hyperhomocysteinemia? YES NO
RISK FACTOR MANAGEMENT
In cases where risk factor management is not straightforward would you wish the involvement of a
vascular physician?
YES NO
Do you have access to a vascular physician? YES NO
Do you have any local guidelines regarding risk factor management in claudicants? YES NO
K. Cassar et al.628
Eur J Vasc Endovasc Surg Vol 26, December 2003
